InvestorsHub Logo
Followers 165
Posts 19842
Boards Moderated 2
Alias Born 12/09/2004

Re: Doc328 post# 444407

Wednesday, 12/27/2023 6:31:40 PM

Wednesday, December 27, 2023 6:31:40 PM

Post# of 463203
The Lecanemab study had only one primary endpoint so it is not quite comparable to the AD study.
The Trofinetide study did have two endpoints however it did not specify any alternative methods of statistical testing. It required both endpoints to meet p<0.05 to proceed to testing the secondary endpoints.

Thank you for linking those two documents.

Success is the best revenge.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News